Purpose: Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia. Materials and Methods: The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6- and 12-month follow-up. Results: Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD − 2.74 CI − 1.95 to − 3.52 in 6 months), fasting plasma glucose levels, body weight (MD − 7.11 CI − 5.97 to − 8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events. Conclusion: This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM.

The purpose of our study was to develop and externally validate a multivariable diagnostic model to distinguish ectopic ACTH secretion (EAS) from Cushing’s disease (CD) using routine clinical parameters. The model was derived from a Spanish multicenter retrospective cohort and externally validated in a Colombian cohort. Predictors were selected through a multivariable logistic regression model with penalized logistic regression (LASSO) using the Spanish cohort. Discriminative performance was assessed using the area under the ROC curve (AUC) and calibration using the slope, the origin, and the Brier score. The derivation cohort included 253 patients from Spain (199 with CD and 54 with EAS). The external validation cohort comprised 72 Colombian patients (53 with CD and 19 with EAS). In the derivation cohort, multivariable modeling identified four independent predictors: ACTH concentration, 24-h urinary free cortisol (UFC), serum potassium, and maximum pituitary tumor diameter. The final model demonstrated good discrimination in the derivation cohort (mean AUC of 0.987), with excellent calibration (calibration slope ranged from 0.998 to 5.22, intercept −0.2 to 0.99, Brier score 0.035). In external validation, model performance remained robust (AUC ranging from 0.9885 to 0.9890; Brier score 0.0381). The model achieved a sensitivity of 95.3%, specificity of 93.6%, positive predictive value of 82.3%, and negative predictive value of 98.7% for detecting EAS. Thus, the diagnostic model developed, based on routinely available clinical variables, shows high accuracy and calibration in differentiating between EAS and CD, supporting its potential use in diverse clinical settings and integration into diagnostic workflows.

Introducción: el abordaje del paciente con diabetes mellitus tipo 2 ha cambiado a lo largo del tiempo. Años anteriores el enfoque terapéutico giraba en torno al nivel de hemoglobina glicada (HbA1c); ahora, con el advenimiento de nuevas moléculas, y luego de entender que la meta terapéutica no es sólo un punto de corte de HbA1c, se ha modificado el objetivo, para estar centrado en el paciente, en sus comorbilidades macro y microvasculares, riesgo cardiovascular y falla cardíaca. En esta revisión de la literatura se exponen las preguntas que se deben resolver al momento de definir una estrategia terapéutica en el paciente con diabetes mellitus tipo 2. Métodos: valoración de guías locales e internacionales de tratamiento de diabetes mellitus tipo 2. Resultados: se valoraron las guías del tratamiento de la diabetes mellitus tipo 2 realizadas por la Asociación Colombiana de Endocrinología, Asociación Colombiana de Medicina Interna, Asociación Colombiana de Nefrología, Sociedad Colombiana de Cardiología y Cirugía Cardiovascular, American Diabetes Association, American Association of Clinical Endocrinology, European Association for the Study of Diabetes y European Society of Cardiology. Además, se revisaron los ensayos clínicos que respaldan el uso de los diferentes grupos farmacológicos disponibles para el tratamiento de los pacientes con diabetes mellitus tipo 2. Conclusión: es menester del clínico realizar el abordaje terapéutico de los pacientes con diabetes mellitus tipo 2 de forma individualizada, centrado en el riesgo cardiovascular, comorbilidades asociadas, riesgo de hipoglucemia y costos de la intervención brindada.

Background/Objectives: Diabetic ketoacidosis (DKA) is an acute and potentially life-threatening complication characterized by the accumulation of ketone bodies in the blood, primarily occurring in patients with type 1 diabetes and occasionally in those with type 2 diabetes under certain conditions. DKA presents with symptoms such as polyuria, polydipsia, polyphagia, and, in severe cases, mental status changes. Identifying the triggering factor is crucial to prevent complications and effectively manage this medical emergency. Methods: This report describes the case of a 58-year-old male patient with stage IIIb nodular melanoma, diagnosed in November 2022. Results: After receiving five cycles of pembrolizumab, the patient developed de novo DKA, presenting with blurred vision, asthenia, adynamia, polyuria, and polydipsia. He was admitted to the emergency department with a blood glucose level of 764 mg/dL, confirming hyperglycemia and metabolic acidosis. He was transferred to the intensive care unit for fluid resuscitation and insulin infusion. After adequate clinical evolution and meeting the criteria for DKA resolution, possible autoimmune endocrinopathies secondary to immunotherapy were considered. Due to this complication, the oncological treatment was changed. Finally, the patient was discharged with the need to continue insulin therapy and oral hypoglycemic agents, along with thyroid hormone supplementation. Conclusions: The novelty of this case lies in the presentation of DKA as an immune-mediated complication induced by pembrolizumab, highlighting the importance of closely monitoring patients receiving immune checkpoint inhibitors to detect and manage emerging autoimmune endocrinopathies. It is essential to adjust oncological treatment according to the patient’s response and promptly manage autoimmune endocrinopathies to improve clinical outcomes and the patient’s quality of life.

Background and Clinical Significance: Endogenous hyperinsulinemic hypoglycemia (HHE) is a rare cause of hypoglycemia, primarily associated with insulinomas, the most common functional pancreatic neuroendocrine tumors. This clinical case explores the diagnostic and therapeutic challenges in patients with recurrent hypoglycemia and no history of diabetes, emphasizing the importance of a multidisciplinary approach to optimize outcomes. Case Presentation: We present a 45-year-old woman presenting with severe hypoglycemic episodes and persistent neuropsychiatric symptoms for over a year. Prolonged fasting tests, insulin and C-peptide level measurements, and specialized imaging studies (endoscopic ultrasound and pancreatic protocol computed tomography) were conducted. Surgical resection of the identified lesion was subsequently performed. Diagnostic studies confirmed a well-differentiated 2.5 cm insulinoma, treated with partial pancreatoduodenectomy. The patient developed postoperative complications that required interdisciplinary management, ultimately achieving clinical stabilization and sustained normoglycemia. Conclusions: This case underscores the importance of considering insulinoma in the differential diagnosis of recurrent hypoglycemia in non-diabetic patients, using Whipple’s triad as a key diagnostic criterion. It also highlights the role played by comprehensive strategies combining functional testing (e.g., prolonged fasting) and advanced imaging to ensure timely treatment and reduce the risk of chronic complications.

Contexto: la tiroiditis posparto es una condición autoinmune que ocurre típicamente dentro de un año posterior al parto, incluso tras un aborto espontáneo. Objetivo: puntualizar la historia natural de la tiroiditis posparto para guiar un mejor abordaje desde la atención primaria y especializada. Metodología: revisión narrativa de los estudios sobre tiroiditis posparto y su historia natural. Se incluyeron artículos publicados en los idiomas inglés y español, publicados en los últimos 20 años hasta enero del 2023. Resultados: se presentaron 33 estudios relacionados con la historia natural de la tiroiditis posparto. Esta patología se ha descrito en mujeres sin enfermedad tiroidea conocida, sin embargo, se ha documentado su desarrollo entre aquellas con hipotiroidismo o tiroiditis de Hashimoto preconcepcional. Su historia natural tiene diversas fases, entre las que destacan una tirotoxicosis transitoria que se puede resolver espontáneamente o pasar a una etapa de hipotiroidismo y, posteriormente, tener un retorno al estado eutiroideo dentro del primer año. Asimismo, puede existir en menor proporción una fase hipotiroidea única que se resuelve también espontáneamente. La evolución hacia el hipotiroidismo permanente (después del primer año posparto) es dependiente de múltiples factores, especialmente de los niveles de tirotropina, anticuerpos antiperoxidasa, multiparidad y edad materna, entre otros. Conclusiones: la tiroiditis posparto es una enfermedad autoinmune común que se desencadena durante el primer año posterior al parto. Usualmente, el curso clínico tiene varias etapas y es fundamental valorar de manera estrecha la función tiroidea posterior al año para definir el requerimiento de continuar suplencia con hormona tiroidea, con una alta tasa de recurrencia con otros embarazos.